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Abstract We previously identified the S-Endo 1-associated
antigen (CD146), an endothelial member of the immunoglobulin
superfamily with a characteristic V-V-C2-C2-C2 Ig domain
structure. In cultured human endothelial cells, we investigated its
biosynthesis by immunoprecipitation and pulse-chase labeling.
CD146 was synthesized as a 100 kDa precursor form, which was
processed into a 120 kDa mature form. In the culture media of
endothelial cells, we observed a CD146 soluble form that was
about 10 kDa smaller than cell-associated CD146. In parallel
with soluble forms of other members of the immunoglobulin
superfamily, soluble CD146 could modulate and control the
functions of the molecule.
z 1998 Federation of European Biochemical Societies.
Key words: Human endothelial cell ; Immunoglobulin
superfamily; Adhesion molecule; Precursor processing;
Soluble CD146
1. Introduction
Vascular endothelium expresses a number of cell adhesion
molecules classi¢ed by their molecular and functional charac-
teristics [1,2]. One major group is the immunoglobulin super-
family (Ig SF) including several members such as intercellular
adhesion molecule-1 and -2, vascular cell adhesion molecule-1,
and platelet endothelial cell adhesion molecule-1 (CD31) [3,4].
Among the members of Ig SF, we have identi¢ed the S-Endo
1-associated antigen [5], recently clustered as CD146 [6]. Orig-
inally described as a marker of melanoma progression [7,8],
this membrane glycoprotein (of around 120 kDa) is expressed
in all types of human endothelial cells [9]. This molecule
shares homology with a subgroup of well-established adhesion
molecules composed of ¢ve Ig domains (V-V-C2-C2-C2) [10^
12]. Its belonging to this subgroup and recent studies suggest
that CD146 may function in adhesion and in intercellular
recognition. First, melanoma cells adhere to the puri¢ed mol-
ecule [13]. Second, CD146 expression increased homotypic
adhesion between cDNA transfected melanoma cells [14].
Third, CD146 is concentrated in the endothelial intercellular
junctions with an increased expression of the molecule at the
cell-cell contact. Fourth, a codistribution of CD146 and ad-
herent junction proteins in early stage of con£uence suggests
that it plays a role in initiating the cell-cell interaction (sub-
mitted). However, although CD146 may play a role in the
vascular adhesion, little is known about its biochemical char-
acterization.
In this report, we investigated the CD146 biosynthesis in
cultured human endothelial cells since membrane glycoproeins
are often synthesized as a precursor molecule [15]. Moreover,
we evaluated whether a soluble CD146 form was produced by
endothelial cells since it is known that soluble forms of adhe-
sion molecules can modulate and control cell adhesion [16].
We found that endothelial cells, ¢rst, express a precursor form
of CD146 and, second, produce a soluble CD146.
2. Materials and methods
2.1. Monoclonal antibodies
The mouse monoclonal IgG1 antibodies used were S-Endo l [17]
raised against CD146, anti-CD31 (Immunotech, Marseilles, France),
and ST4 raised against CD4 (Biocytex, Marseilles, France).
2.2. Cell culture
Endothelial cells (HUVECs) were harvested from human umbilical
cord vein as previously described [18]. HUVECs were maintained in
RPMI 1640 containing 20% fetal calf serum (FCS). Myeloid U937
cells, CD146 negative, were maintained in RPMI 1640 supplemented
with 10% FCS. To detect soluble CD146, supernatants of con£uent
cultured cells were ¢ltered on 0.22 Wm ¢lters, centrifuged at
100 000Ug for 90 min and concentrated about 10-fold with a Centri-
sart (100 000) (Sartorius, Goºttingen, Germany). Samples were stored
at 320‡C.
2.3. Western blotting
Con£uent cells were solubilized for 20 min at 4‡C in RIPA bu¡er
containing protease inhibitors as previously described [5]. Brie£y, ly-
sates were centrifuged at 100 000Ug for 30 min. Supernatants were
electrophoresed on a 6.7% SDS-polyacrylamide gel, under reducing
conditions (8% L2-mercaptoethanol) or non-reducing conditions and
transferred on nitrocellulose membranes. Membranes were incubated
for 1 h with 1 Wg/ml of S-Endo 1 and for 45 min with 1:5000 horse-
radish peroxidase anti-mouse Ig (Amersham, les Ulis, France). The
blots were revealed with chemiluminescent substrate (Valbiotech,
Paris, France).
2.4. Metabolic labeling and pulse-chase experiments
HUVECs (6U106 at about 75% of con£uence) were preincubated
with DME medium without methionine and cysteine for 1 h at 37‡C
and then metabolically labeled with 25 WCi/ml [35S]methionine and
[35S]cysteine (Amersham) for 4 h [19]. For biosynthetic studies,
starved HUVECs were pulsed with 1 mCi/ml [35S]amino acids for
15 min and chased for 1 h and 4 h in DME medium supplemented
with methionine and cysteine. After lysis in RIPA bu¡er containing
protease inhibitors, antigens were immunoprecipitated by using mAbs
and anti-mouse IgG1 sepharose beads (Pharmacia, St. Quentin Yve-
lines, France). They were then eluted with Laemmli’s bu¡er and an-
alyzed on a 6.7% SDS-polyacrylamide gel. Gels were ¢xed (40% meth-
anol, 10% acetic acid) and dried before exposure on a Kodak X-ray
¢lm at 380‡C. In some experiments, immunoprecipitated CD146 was
incubated at 37‡C overnight with endoglycosidase H (4 mU, Boeh-
ringer Mannheim, Meylan, France) in 50 mM sodium citrate pH 5.5,
1% Triton X-100, 0.1% L2-mercaptoethanol, 1 mM PMSF.
2.5. Peptide mapping
This mapping was performed according to the Cleveland modi¢ed
procedure, using Staphylococcus aureus V8 protease [20]. Brie£y, [35S]-
labeled antigens immunoprecipitated and separated on SDS-PAGE
were excised from dried gel and transferred into the stacking of a
second gel. Proteins were digested for 30 min with comigrated pro-
tease in reducing conditions. Peptide maps were then analyzed.
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3. Results
In previously Western blot experiments on HUVEC lysates,
we found that S-Endo 1 speci¢cally recognized a major pro-
tein of about 120 kDa (CD146), and a minor protein of about
100 kDa presenting a variable intensity [5]. Metabolic labeling
was performed on HUVECs followed by speci¢c immunopre-
cipitation (Fig. 1). Under non-reducing conditions, two pro-
teins of 120 kDa and 100 kDa were immunoprecipitated with
S-Endo 1 (lane 1). Under reducing conditions, their electro-
phoretic mobility was respectively increased to 130 and 110
kDa (lane 2), indicating intracatenar disul¢de bonds. As con-
trol, two di¡erent proteins (135 and 125 kDa) were revealed
when labeled HUVECs were immunoprecipitated with CD31
under reducing conditions (lane 3). Clearly, our results indi-
cate that the 100/110 kDa protein (p100) speci¢cally precip-
itates with CD146, the 120/130 kDa protein (p120). These
data raised two hypotheses: either p100 coprecipitated with
CD146 because it reacts directly with S-Endo 1, or p100 is
physically associated with CD146. To distinguish between
these hypotheses, several experiments were performed. First,
we dissociated the labeled complex in 0.1% SDS for 5 min at
100‡C and precipitated it with S-Endo 1 (Fig. 2). p100 was
revealed in undissociated (lane 1) as well as dissociated (lane
2) immunoprecipitated CD146, indicating that p100 shared
with p120 a common epitope recognized by S-Endo 1. Second,
we performed partial proteolysis of p100 and p120. The com-
parison of peptide maps showed structural similarities (Fig.
3), suggesting that the two proteins are partially identical.
Third, S-Endo 1 immunoprecipitation performed after cross-
linking experiments indicated that CD146 is expressed at the
cell surface as a monomeric structure of about 120 kDa (data
not shown). Fourth, to determine whether p100 and p120
represent two steps of maturation of the same protein, HU-
VECs were pulsed 15 min and chased for various times in
reducing conditions (Fig. 4). Pre-CD146 was detected within
15 min at a molecular weight of 110 kDa (lane 1). Signi¢cant
levels of mature form of 130 kDa appeared after 1 h of chase
(lane 2). After 4 h, only the mature form persisted (lane 4). In
addition, when labeled HUVECs were treated with endo H,
which cleaves high-mannose carbohydrate moieties, only the
precursor form presented a signi¢cant faster migration (Fig. 4,
lane 3). As controls, CD31 immunoprecipitated a protein of
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Fig. 1. Immunoprecipitation of CD146. [35S]-labeled HUVECs were
immunoprecipitated with S-Endo 1 in non-reducing (lane 1) and re-
ducing conditions (lane 2) and with anti-CD31 in reducing condi-
tions (lane 3), followed by SDS-6.67%-PAGE analysis.
Fig. 2. Dissociation of the CD146-labeled complex. The CD146 im-
munoprecipitated with labeled HUVECs (lane 1) was dissociated in
0.1% SDS for 5 min at 100‡C. It was immunoprecipitated a second
time with S-Endo 1 (lane 2) and analyzed by SDS-PAGE.
Fig. 3. Peptide mapping. A: The p100- (a) and p120- (b) labeled
proteins were excised from the wet gel. B: The proteins (a and b)
were incubated with increasing concentrations of protease and elec-
trophoresed in order to obtain their peptide maps.
Fig. 4. Biosynthesis of CD146. HUVECs were pulsed with
[35S]amino acids for 15 min (lane 1) and chased for 1 h (lanes 2, 3)
and 4 h (lanes 4, 5, 6). Cells were then immunoprecipitated with S-
Endo 1 (lanes 1, 2, 4), anti-CD31 (lane 5) or ST4 (lane 6) and SDS-
PAGE analyzed. Endo H treatment was performed on S-Endo 1 im-
munoprecipitated (lane 3).
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about 135 kDa and irrelevant mAb did not reveal any band
(lanes 5 and 6, respectively). Taken together, these results
show that p100 and p120 represent two maturation states of
CD146.
To examine whether a soluble form of CD146 might be
synthesized by endothelial cells, we performed a two-site sand-
wich ELISA on HUVEC supernatants. Before concentration,
samples of supernatants were ¢ltered and ultracentrifuged to
remove cell debris. The ELISA detected a soluble form of the
molecule (data not shown). To verify the speci¢city of detec-
tion, Western blot analysis was undertaken on these super-
natants previously immunoprecipitated by S-Endo 1 (Fig. 5).
Soluble CD146, detected in the HUVEC culture media (lane
2), migrated more rapidly (around 105 kDa) than the corre-
sponding cell-associated form (lane 1). As expected, no band
was observed in lysates and supernatants of U937 cells used as
negative control (lanes 3 and 4, respectively).
4. Discussion
We show that CD146 is synthesized by cultured endothelial
cells as a precursor form (p100) further processed into a ma-
ture glycoprotein (p120) expressed at the cell membrane. We
also demonstrated that CD146 is found in a soluble form
(p105) in the culture media.
The pre-CD146 (p100) is supported by several lines of evi-
dence. The two proteins immunoprecipitated by S-Endo 1,
p100 and p120, shared common epitopes. Their peptide map
revealed structural identities. Only the p120 is expressed at the
cell membrane. Study of CD146 synthesis showed that the
precursor form, p100, can be detected in as little as 15 min.
It was then converted into p120 within 4 h. Analysis of the
glycosylation pattern indicated that only p100 is sensitive to
endo H digestion. Probably, high-mannose carbohydrate moi-
eties allow p100 to be further processed in the Golgi appara-
tus [15], resulting in the mature form of CD146.
In a submitted manuscript, we described the progressive
organization and accumulation of CD146 at the endothelial
junction and reported the relative stability of its total amount.
These results compared to the rapid kinetics of CD146 syn-
thesis suggest a large turn-over of the molecule, which could
be regulated by secretion or by proteolysis of the membrane
form. Indeed, we observed a soluble CD146, about 10 kDa
smaller than the corresponding cell-associated form. Mecha-
nisms leading to the production of soluble CD146 are under
investigation. Discovery of a soluble form in the culture media
prompted us to look for soluble CD146 in normal human
plasma and preliminary experiments are in agreement with
its presence in healthy donors.
Soluble forms of adhesion molecules may function as com-
petitive inhibitors of membrane-bound forms, thereby regulat-
ing cell adhesion [21]. This has been demonstrated for the
soluble form of P-selectin, which is able to inhibit the adhe-
sion of activated neutrophils to endothelial cells [22]. In the
same way, soluble CD31 was able to inhibit the heterotypic
adhesion mediated by the cell surface CD31 expressed on
transfected cells [15]. As there is evidence that CD146 plays
a role in cell adhesion [13,14], we can suppose that the soluble
form acts in modulating and controlling CD146 functions
during adhesive interactions of human endothelial monolayer.
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Fig. 5. Soluble CD146 detection. HUVEC supernatants were immu-
noprecipitated with S-Endo 1 (lane 2) and compared to the corre-
sponding cell form (lane 1) after Western blotting. U937 lysate (lane
3) or supernatants (lane 4), used as controls, were treated under the
same conditions.
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